The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Open accessAbstract
BACKGROUND: alteration. Data are needed to confirm and expand on the findings of the phase 2 study. METHODS: alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). We randomly assigned the patients in a 2:1 ratio to receive oral rucaparib (600 mg twice daily) or a physician's choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival according to independent review. RESULTS: alteration. At 62 months, the duration of imaging-based progression-free survival was significantly longer in the rucaparib group than in the control group, both in the BRCA subgroup (median, 11.2 months and 6.4 months, respectively; hazard ratio, 0.50; 95% confidence interval [CI], 0.36 to 0.69) and in the intention-to-treat group (median, 10.2 months and 6.4 months, respectively; hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001 for both comparisons). In an exploratory analysis in the ATM subgroup, the median duration of imaging-based progression-free survival was 8.1 months in the rucaparib group and 6.8 months in the control group (hazard ratio, 0.95; 95% CI, 0.59 to 1.52). The most frequent adverse events with rucaparib were fatigue and nausea. CONCLUSIONS: alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 3 randomized trials PROfound (NCT02987543), and TRITON-3 (NCT02975934), treatment with PARP inhibitors was favored in both chemotherapy-naïve patients and those who had received prior taxane-based chemotherapy [57, 58].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an exploratory analysis of a subgroup of TRITON-3 evaluating patients with BRCA alterations, the median PFS with rucaparib (11.2 months) was longer than with docetaxel (6.4 months; p < 0.001) [57].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationAshworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Flagged first, then by citations
Research works printed but not linked: 2
- Rubraca (rucaparib) tablets. Boulder, CO: Clovis Oncology, 2022 (package insert).
- Lynparza (olaparib) tablets. Wilmington, DE: AstraZeneca Pharmaceuticals, 2022 (package insert).
Cited by
Sorted by citations
Items 201–300 of 452
20 years of taxane therapy in prostate cancer — the past, present and future
Carceles‐Cordon, M., Rodríguez-Bravo, V., Petrylak, D. P., & Domenech, J. M. D. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01104-9 · Cited by 4
Innate immunity in tumour immunoediting and immunosurveillance
Zhang, Z., Zhang, Y., & Lieberman, J. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00650-7 · Cited by 4
The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition
Giuntini, F., Whitfield, J. R., Massó-Vallés, D., & Soucek, L. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1726515 · Cited by 5
Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness
Costanzo, F. D., Williamson, J., Robson, C. N., Gaughan, L., Conteduca, V., Mansour, W. Y., Formisano, L., Demichelis, F., Oing, C., & Rescigno, P. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0724 · Cited by 4
Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer
Thapa, B., Venturini, J., Choudhury, A. D., & Francini, E. (2026) · Cancers · doi:10.3390/cancers18111702 · Cited by 4
Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre
Wang, X., Waldman, L., Silberman, Y., Wang, M. L., Tackey, C., Hanna, L., Vesprini, D., Emmenegger, U., Eisen, A. F., & Smoragiewicz, M. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.02.003 · Cited by 4
Self-citationThe Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Yu, E.-M., Patel, I., Hwang, M. W., Polani, F., & Aragon‐Ching, J. B. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241277181 · Cited by 4
Immunotherapy in metastatic prostate cancer
Dwyer, L., Leslie, C., Mellor, R., Scheinberg, T., Taylor, R. A., & Horvath, L. G. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251347857 · Cited by 4
Al-Ezzi, E. M., Abdeljalil, O., Lajkosz, K., Gramolini, S. S., Alqaisi, H. A., Peng, J., O’Dwyer, R., Alghamdi, M., Almuthri, S. A., Kumar, V., et al. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.06.004 · Cited by 4
Self-citationMehra, N., Antonarakis, E. S., Park, S. H., Goh, J. C. H., McDermott, R., González, N. S., Fong, P. C. C., Greil, R., Santis, M. D., Yanez, P. E., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.04.018 · Cited by 4
Self-citationChen, X., Pan, Y., Wang, Q., Ren, C., Li, M., Hao, X., Xie, L., & Liu, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1225033 · Cited by 4
Liu, Y., Deng, X., Wen, Z., Huang, J., Wang, C., Chen, C., Bao, E., Wang, J., & Yang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1290990 · Cited by 4
Yang, J., Xiong, X., Zheng, W., Liao, X., Xu, H., Yang, L., & Wei, Q. (2023) · Current Oncology · doi:10.3390/curroncol30120751 · Cited by 4
Mustafa, M. T., Abushanab, A. K., Mousa, M. T., Qawaqzeh, R. A., Alakhras, H. M., Othman, A. S., & Saed, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2309177 · Cited by 4
Ali, A., Elumalai, T., Venkatesulu, B., Hekman, L., Mistry, H. B., Sachdeva, A., Oliveira, P., Clarke, N. W., Baena, E., Choudhury, A., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000193 · Cited by 4
Chiong, E., Murphy, D. G., Buchan, N. C., Chen, K. S.-M., Chen, S. S., Chua, M. L. K., Hamid, A. R. A. H., Kanesvaran, R., Khochikar, M., Letran, J. L., et al. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14064 · Cited by 4
Talazoparib for the treatment of prostate cancer
Narang, A., Chehade, C. H., Özay, Z. İ., Nordblad, B., Swami, U., & Agarwal, N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2397002 · Cited by 4
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers
Chowdhury, D., Chin, L. D., Odabashian, R., Fawaz, A., Canil, C., Ong, M., Kirchhof, M. G., Reaume, M. N., Beltran-Bless, A.-A., Savard, M.-F., et al. (2025) · Cancers · doi:10.3390/cancers17020251 · Cited by 4
Self-citationGiorgi, U. D., Giunta, E. F., Verzoni, E., & Procopio, G. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.008 · Cited by 4
Boiarsky, D., Tewari, A. K., Gulhan, D. C., Bakouny, Z., Ananda, G., Savignano, H., Lakshminarayanan, G., McClure, H. M., Silver, R., Choueiri, T. K., et al. (2024) · The Prostate · doi:10.1002/pros.24788 · Cited by 4
Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
Qureshi, Z. A., Fatima, E., Safi, A., Khanzada, M., & Altaf, F. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001159 · Cited by 3
Jiang, B., Wang, B., Chen, Y., Chen, Y., Li, B., & Bi, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103129 · Cited by 3
PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer
Okuda, Y., Kato, T., Ishizuya, Y., Hayashi, T., Yamamoto, Y., Hatano, K., Kawashima, A., Murai, J., & Nonomura, N. (2025) · International Journal of Urology · doi:10.1111/iju.70100 · Cited by 4
Prostate cancer germline variants with therapeutic implications
Bitaraf, M., Castro, E., & Sharifi, N. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.004 · Cited by 3
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations
Ostrowski, M., Jo, Y., Chehade, C. H., Özay, Z. İ., Gebrael, G., Sayegh, N., Lin, E., Srivastava, A., Gordhamer, A., Ji, R., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.34968 · Cited by 3
Neumann, C. M., Dedousis, D., & Hall, M. J. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00951 · Cited by 3
Spiekman, I. A. C., Mehra, N., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Mohammad, S. F. H., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70191 · Cited by 3
Germline Mutations as Cancer Drug Targets
Tang, T., Maresso, K. C., Ngeow, J. Y. Y., Vilar, E., & Yap, T. A. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1241 · Cited by 3
Tao, W., Sabel, A. R., & Bonfil, R. D. (2025) · Current Oncology · doi:10.3390/curroncol32120692 · Cited by 3
Cellular signaling and radioresistance in prostate cancer
Sosa, G. A., Crosswhite, B., & Kirschner, A. N. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112367 · Cited by 3
Carrizosa, D. R., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Behl, D., Adesunloye, B. A., Pisick, E. P., Beekman, K. W., Dotan, E., Akce, M., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00716 · Cited by 3
AI-Driven Drug Discovery: Focus on Targets for Solid Tumors
Wu, J., He, J., Ni, Q., Li, Z., Lin, X., Zhao, Z., Qiu, L., WANG, H., Li, S., Shi, C., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030329 · Cited by 3
Liquid Biopsy in Advanced Prostate Cancer
Mediavilla-Medel, P., García‐Simón, N., González-del-Alba, A., & Romero, A. (2026) · Cancers · doi:10.3390/cancers18091366 · Cited by 3
Shore, N. D., Fizazi, K. S., Schweizer, M. T., Castro, E., Azad, A. A., George, D. J., da Trindade, K. M., Zeng, H., Shrivastava, N., Tonkovyd, S., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2667441 · Cited by 3
Self-citationVlaming, M., Ausems, M. G. E. M., Schijven, G., van Oort, I. M., Kets, C. M., Komdeur, F. L., van der Kolk, L. E., Oldenburg, R. A., Sijmons, R. H., Kiemeney, L. A. L. M., et al. (2024) · Familial Cancer · doi:10.1007/s10689-024-00377-0 · Cited by 3
ZBP1 as a prognostic biomarker correlated with cell proliferation in clear cell renal cell carcinoma
Zhang, Y., Wang, T., Mutailipu, D., Li, Y., Liang, S., Yi, Q., Zhu, R., & Ma, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39267 · Cited by 3
Saporita, I., Calabrese, M., Poletto, S., Turco, F., Stefano, R. F. D., Caffo, O., Russo, A. G., Giorgi, U. D., Tucci, M., Maïo, M. D., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102255 · Cited by 3
Vlaming, M., Ausems, M. G. E. M., Kiemeney, L. A. L. M., Schijven, G., van Melick, H. H. E., Noordzij, M. A., Somford, D. M., van der Poel, H. G., Wijburg, C. J., Wijsman, B. P., et al. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00925-w · Cited by 3
Xiao, D., Chu, X., Wang, W., Peng, M., Lv, Q., Xu, C., Duan, H., & Yang, X. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.105072 · Cited by 3
Pinterpe, G., Migliaccio, F., Ciccarese, C., Pedone, R. R., Belletto, R., Russo, P., Totaro, A., Tagliaferri, L., Sighinolfi, M. C., Formisano, L., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01141-9 · Cited by 3
Fountzilas, E., Kouspou, M., Eliades, A., Papadopoulou, K., Bournakis, E., GOUSSIA, A. C., Tsiatas, M. L., Achilleos, A., Tsangaras, K., Billioud, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411834 · Cited by 3
Castration resistant prostate cancer: recent advances in novel therapeutic treatments
Fatima, H., Rangwala, H. S., Riaz, F., Ali, L., Abbas, S. R., & Haque, S. U. (2024) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000400 · Cited by 3
Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives
STEFANOVIĆ, N. Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-51712-9_17 · Cited by 3
Aprikian, A. G., Fred Saad, C., Wywiał, E., McLean, T., Johnston, K., Li, Y., & Chilelli, A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2503660 · Cited by 3
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., & Parikh, R. A. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00747 · Cited by 3
Prostate Cancer: Advances in Genetic Testing and Clinical Implications
Abdelrazek, A., Ghoniem, K., Ahmed, M. E., Joshi, V. B., Mahmoud, A. M., Saeed, N., Khater, N. P., ElSharkawy, M. S., Gamal, A., Kwon, E. D., et al. (2023) · Uro · doi:10.3390/uro3020012 · Cited by 3
Bryce, A. H., Crawford, E. D., Agarwal, N., Hussain, M., Beltran, H., Cooperberg, M. R., Petrylak, D. P., Shore, N. D., Spratt, D. E., Tagawa, S. T., et al. (2024) · JU Open Plus · doi:10.1097/ju9.0000000000000138 · Cited by 3
Self-citationAre PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not
González‐Padilla, D. A., & Subiela, J. D. (2023) · European Urology · doi:10.1016/j.eururo.2023.05.017 · Cited by 3
Sayyid, R. K., Bernardino, R. M. M., Chavarriaga, J., Gleave, A., Kumar, R., & Fleshner, N. E. (2024) · Translational Andrology and Urology · doi:10.21037/tau-23-671 · Cited by 3
Smith, S. C., Melson, J. W., Quillin, J. M., Hiemenz, M., Tomlins, S. A., & Wobker, S. E. (2025) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqae186 · Cited by 2
Einspieler, H., Ofner, H., Ozenil, M., Spielvogel, C. P., Langrate, I. K., Hassler, M. R., Nics, L., Bamminger, K., Baltzer, P., Shariat, S. F., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07448-z · Cited by 3
Yazgan, S. C., Yekedüz, E., Akkuş, E., Sun, M., Gillessen, S., Fizazi, K. S., McKay, R. R., Ay, C., Castro, E., Agarwal, N., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105811 · Cited by 2
Self-citationMcGehee, C. D., Meng, X. W., Wu, X., Correia, C., Venkatachalam, A., Flatten, K. S., Peterson, K. L., Patel, A. G., Rossman, O. K., Wong, C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf990 · Cited by 2
Navigating the winding road toward precision prostate cancer care
Rahman, S. N., Arun, A. S., Kim, I. Y., Oh, W. K., Kim, J. W., & Kim, W. J. (2025) · Gene · doi:10.1016/j.gene.2025.149966 · Cited by 2
Zou, Y., Wang, H., Hu, M., Lu, K., Li, M., Chen, W., & Tian, R. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01552 · Cited by 2
Lin, D. I., Lawrence, E., Danziger, N. A., Ye, H., Decker, B. J., Gjoerup, O. V., Graf, R. P., Ross, J. S., Huang, R. S. P., Elvin, J. A., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71489 · Cited by 2
Yi, X., Han, Z., Lu, D., Xu, H., Zheng, X. S., Tang, Y., Li, J., Li, X., Liao, D., Li, H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.003 · Cited by 2
PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges
Matsuoka, T., Akamatsu, S., Ong, C. J., Gleave, M. E., & Wang, Y. (2026) · Cells · doi:10.3390/cells15070588 · Cited by 3
Evaluation of novel treatments for metastatic castration-resistant prostate cancer
Güner, G., & Arslan, Ç. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2652456 · Cited by 2
Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?
Myat, Y. M., Thein, K. Z., Han, M. M., Ahluwalia, M. S., Mukherjee, S., & Aung, K. L. (2026) · Cancers · doi:10.3390/cancers18101568 · Cited by 2
Somoto, T., Utsumi, T., Ikeda, R., Sugimoto, T., Ishitsuka, N., Kadono, Y., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., et al. (2026) · Cancers · doi:10.3390/cancers18121966 · Cited by 2
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
Hooper, G., Jo, Y., Nandakumar, V., Gebrael, G., Özay, Z. İ., Ostrowski, M., Hardy, T., Lin, E., Campbell, P., Murdock, E. G., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.20750 · Cited by 2
Mercinelli, C., Costanzo, F. D., Oing, C., Guandalini, G., Maiorano, B. A., Sammarco, E., Salfi, A., Serafin, D., Tateo, V., Cigliola, A., et al. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2695214 · Cited by 2
Advances in systemic therapies for advanced prostate cancer
Childs, D. S., Hahn, A. W., Ravi, P. K., & Orme, J. J. (2026) · BMJ · doi:10.1136/bmj-2025-085211 · Cited by 2
The DNA damage response and cancer immunotherapy
Sheng, H., & Li, G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00958-4 · Cited by 3
Paras, G., & Schweizer, M. T. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.07.014 · Cited by 2
Zielgerichtete Therapieoptionen in der Uroonkologie
Franz, A., Plage, H., Fendler, A., Schlomm, T., & Furlano, K. (2023) · Die Urologie · doi:10.1007/s00120-023-02119-z · Cited by 2
Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer
Akbıyık, İ., & Ürün, Y. (2023) · Future Oncology · doi:10.2217/fon-2023-0550 · Cited by 2
Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer
Januškevičius, T., Vaicekauskaitė, I., Sabaliauskaitė, R., Matulevičius, A., Vėželis, A., Ulys, A., Jarmalaitė, S., & Jankevičius, F. (2023) · Medicina · doi:10.3390/medicina60010073 · Cited by 2
Baude, J., Niogret, J., Jacob, P., Bardet, F., Desmoulins, I., Zanetta, S., Kaderbhaï, C., Galland, L., Mayeur, D., Delattre, B., et al. (2024) · Cancers · doi:10.3390/cancers16020280 · Cited by 2
Molecular uropathology: what a practising pathologist should know
Bahlinger, V., Lange, F., & Eckstein, M. (2024) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2024.02.003 · Cited by 3
Molekulare Testung des Prostatakarzinoms: wann, wie und mit welcher Konsequenz?
Amsberg, G. V., & Paulsen, F. (2024) · Aktuelle Urologie · doi:10.1055/a-2266-3607 · Cited by 2
Germline and somatic mutations in prostate cancer: Implications for treatment
Chalker, C., Chun, B., & Sokolova, A. O. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101101 · Cited by 2
Targeted DNA damage repair: old mechanisms and new opportunities in clear cell renal cell carcinoma
Lv, J., Gong, P., Jia, G., & Li, W. (2024) · Genome Instability & Disease · doi:10.1007/s42764-024-00138-4 · Cited by 2
PARP inhibitors in prostate cancer: clinical applications
Saeidi, H., & Sarafbidabad, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10034-5 · Cited by 2
Yanev, I., Aprikian, A. G., Raizenne, B. L., & Dragomir, A. (2024) · Cancers · doi:10.3390/cancers17010040 · Cited by 2
Yang, C., Lai, H., Yang, X., Huang, Y., Shi, Y., Ke, L., Chen, L., Chen, M., Chen, H., & Wang, Q. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141557 · Cited by 2
Autio, K. A., McHugh, D. J., Rathkopf, D. E., Xiao, H., Merugu, S., Wong, P., Jan, M., Dorff, T. B., Heath, E. I., & Scher, H. I. (2025) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-24-36 · Cited by 2
Toxicities of PARP inhibitors in genitourinary cancers
Szalontai, J., Szarvas, T., Miszczyk, M., Nyírády, P., Shariat, S. F., & Fazekas, T. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001297 · Cited by 2
The history of targeted therapy
Gerk, I. (2023) · Practical oncology · doi:10.31917/2402119 · Cited by 2
Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique
Denis, C., & Sautois, B. R. (2023) · Médecine Nucléaire · doi:10.1016/j.mednuc.2023.09.003 · Cited by 3
Self-citationTalazoparib plus enzalutamide for metastatic castration-resistant prostate cancer: TALAPRO-2 trial
Gupta, P. (2023) · Indian Journal of Urology · doi:10.4103/iju.iju_307_23 · Cited by 2
Panebianco, M., Cereda, V., & D'Andrea, M. R. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00260 · Cited by 3
dos Reis, R. B., Aguilar-Ponce, J. L., Cayol, F., Jansen, A. M., Ray Manneh, K., Merino, T. R., Sanku, G., Vaca, L. B., Velho, P. I., & Korbenfeld, E. P. (2024) · Cancer Control · doi:10.1177/10732748241280446 · Cited by 2
Jo, Y., Chipman, J., Haaland, B. A., Greene, T., & Kohli, M. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00399 · Cited by 2
Genomic and transcriptomic sequencing in prostate cancer
Rifai, S., Rifai, A., Shi, X., Khan, M. A., Guang, W., Wang, L., Tallon, L. J., & Hussain, A. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001136 · Cited by 2
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced
Goel, K., Venkatappa, V., Krieger, K. L., Chen, D., Sreekumar, A., & Gassman, N. R. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf015 · Cited by 2
Fizazi, K. S., Bono, J. S. D., Laird, A., Barthélémy, P., Delva, R., Dorff, T. B., Maruzzo, M., Stirling, A., Machiels, J., Dumez, H., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.09.016 · Cited by 2
Self-citationGenetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Han, H. H., Kang, M., Byun, S., & Yun, S. J. (2023) · Journal of Urologic Oncology · doi:10.22465/juo.234600340017 · Cited by 2
Qu’est-ce que 2023 aura permis de changer dans nos pratiques en cancérologie ?
Bay, J., Auberger, B., Bouleuc, C., Cohen, R., Delom, F., Firmin, N., Gandemer, V., L’Allemain, G., Magné, N., de Nonneville, A. T., et al. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.12.003 · Cited by 2
Yan, K., Balijepalli, C., Gullapalli, L., Joshy, J., Kotum, S., & Druyts, E. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2395435 · Cited by 2
Yan, H., Mao, A., Li, D., Pérez‐Baena, M. J., Jiménez‐Navas, A., Wang, D., Hong, R., Cai, W., Pérez‐Losada, J., Jen, K., et al. (2024) · medRxiv · doi:10.1101/2024.11.17.24317411 · Cited by 2
Shao, C., Ren, Y., Zhou, H., Lee, L. C., Chen, C., Dettman, E. J., Cristescu, R., Gozman, A., Jin, F., & Zhou, W. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02734-4 · Cited by 1
Machine Learning based on Probabilistic Models Applied to Medical Data: The Case of Prostate Cancer
Bikengela, A. T., Tshimona, R. M., Katalay, P. K., Badibanga, S. N., & Mukendi, E. M. (2023) · Journal of Innovation Information Technology and Application (JINITA) · doi:10.35970/jinita.v5i2.1879 · Cited by 1
Morini, M. A., Athanazio, D. A., Gallas, L. F., Mota, J. M., Bezerra, S. M., Lobo, J., Froján, M. B. M., & Acosta, A. M. (2024) · Surgical and Experimental Pathology · doi:10.1186/s42047-024-00158-0 · Cited by 1
Wang, Q., Ye, J., Zheng, L., Tu, X., Zeng, H., Bao, Y., & Wei, Q. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00119-3 · Cited by 1
Poly-ADP Ribose Polymerase Inhibitors and Combinations in Metastatic Prostate Cancer
Ababneh, O. E., & McKay, R. R. (2025) · Advances in Oncology · doi:10.1016/j.yao.2024.12.008 · Cited by 1
Vellky, J. E. (2025) · American Journal of Clinical and Experimental Urology · doi:10.62347/pukg7105 · Cited by 1
Virga, A., Urbini, M., Polano, M., Petracci, E., Tedaldi, G., Gurioli, G., Marisi, G., Angeli, D., Ambrosini‐Spaltro, A., Luca, G. D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05384-4 · Cited by 2
Autio, K. A., Kyriakopoulos, C. E., Palyca, P., Xiao, H., Emamekhoo, H., Danila, D. C., Jan, M., Catharine, V., Riedel, E., Devitt, M. E., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01580-1 · Cited by 1
Metadata
- Authors
- Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., Krieger, L., Sautois, B., Loehr, A., Despain, D., Heyes, C. A., Watkins, S. P., Chowdhury, S., Ryan, C. J., & Bryce, A. H.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Guy's Hospital (GB)
- University of Minnesota (US)
- ORCID
- Fizazi, Karim
- Piulats, Josep M.
- Reaume, M. Neil
- Ostler, Peter
- McDermott, Ray
- Gingerich, Joel R.
- Pintus, Elias
- Sridhar, Srikala S.
- Bambury, Richard M.
- Emmenegger, Urban
- Lindberg, Henriette
- Morris, David
- Nolè, Franco
- Staffurth, John
- Abida, Wassim
- Daugaard, Gedske
- Heidenreich, Axel
- Krieger, Laurence
- Sautois, Brieuc
- Loehr, Andrea
- Despain, Darrin
- Watkins, Simon P.
- Ryan, Charles J.
- Bryce, Alan H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-02-23
- Volume
- 388
- Issue
- 8
- Pages
- 719-732
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10064172
- OpenAlex
- W4321079951
- Cited by
- 449
- References
- 27
- Citations by year
- 2026: 91 · 2025: 134 · 2024: 139 · 2023: 85
- FWCI
- 82.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- Funders
- Clovis Oncology
- National Cancer Institute (P30-CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- rucaparib, metastatic prostate cancer, PARP inhibitors, BRCA mutations, ATM mutations, progression-free survival, androgen receptor pathway inhibitors, docetaxel, abiraterone, enzalutamide, PARP inhibitor resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Docetaxel, Progression-Free Survival, Androgen Antagonists, Androstenes, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Indoles, Male, Nitriles, Phenylthiohydantoin, Disease Progression, Genes, BRCA1, Genes, BRCA2, Ataxia Telangiectasia Mutated Proteins, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
